Pharmacologically Active Drug Metabolites: Impact on Drug
... Address correspondence to: Dr. R. Scott Obach, Pfizer Inc., Eastern Point Rd., Groton, CT 06340. E-mail: [email protected] dx.doi.org/10.1124/pr.111.005439. ...
... Address correspondence to: Dr. R. Scott Obach, Pfizer Inc., Eastern Point Rd., Groton, CT 06340. E-mail: [email protected] dx.doi.org/10.1124/pr.111.005439. ...
Glucosamine sulfate.fm
... reversal of the pro-inflammatory and jointdegenerating effects of interleukin (IL)-1 [18,25,26]. More specifically, it inhibits the cytokine intracellular signaling cascade, namely the activation of the nuclear factor (NF)-κB pathway [27]. In particular, glucosamine sulfate has been shown to inhibit ...
... reversal of the pro-inflammatory and jointdegenerating effects of interleukin (IL)-1 [18,25,26]. More specifically, it inhibits the cytokine intracellular signaling cascade, namely the activation of the nuclear factor (NF)-κB pathway [27]. In particular, glucosamine sulfate has been shown to inhibit ...
XOPENEX®(levalbuterol HCI)
... 6-11 years old is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day. Adults and Adolescents ≥12 years old: The recommended starting dosage of XOPENEX Inhalation Solution for patients 12 years of age and older is 0.63 mg administered t ...
... 6-11 years old is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day. Adults and Adolescents ≥12 years old: The recommended starting dosage of XOPENEX Inhalation Solution for patients 12 years of age and older is 0.63 mg administered t ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These
... Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (5.1) TRUVADA is not approved for the treatment of chronic hepatitis B virus (HBV) infection. Severe acute exacerbations of ...
... Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, a component of TRUVADA. (5.1) TRUVADA is not approved for the treatment of chronic hepatitis B virus (HBV) infection. Severe acute exacerbations of ...
available pharmaceutical products
... merger attempt with Allos was ended in November 2011. On Nov 17, 2011, AMAG announced that it had hired Jefferies to explore all opportunities to enhance shareholder value. Frank Thomas, interim CEO of AMAG indicated: “We will expeditiously complete this process, which will include a parallel review ...
... merger attempt with Allos was ended in November 2011. On Nov 17, 2011, AMAG announced that it had hired Jefferies to explore all opportunities to enhance shareholder value. Frank Thomas, interim CEO of AMAG indicated: “We will expeditiously complete this process, which will include a parallel review ...
Dapagliflozin (as propanediol monohydrate) / Metformin hydrochloride
... Mechanism of Action XIGDUO XR combines two anti-hyperglycaemic agents with complementary mechanisms of action to improve both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) in patients with type 2 diabetes: dapagliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member o ...
... Mechanism of Action XIGDUO XR combines two anti-hyperglycaemic agents with complementary mechanisms of action to improve both fasting plasma glucose (FPG) and postprandial plasma glucose (PPG) in patients with type 2 diabetes: dapagliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member o ...
Data Sheet Name of Medicine Presentation
... that enhanced patient compliance. Patients with psychosis, dementia, and secondary psychiatric diagnoses were excluded from these studies. In one of these studies, 104 alcohol-dependent patients were randomised to receive either Naltrexone Hydrochloride 50mg once daily or placebo.In this study, Nalt ...
... that enhanced patient compliance. Patients with psychosis, dementia, and secondary psychiatric diagnoses were excluded from these studies. In one of these studies, 104 alcohol-dependent patients were randomised to receive either Naltrexone Hydrochloride 50mg once daily or placebo.In this study, Nalt ...
Prescribing Information
... episodic congestive heart failure, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline ...
... episodic congestive heart failure, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (serum alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline ...
NALTREXONE HYDROCHLORIDE TABLETS USP 50 mg Rx only
... alcohol-dependent patients, the group of patients receiving naltrexone were shown to have lower relapse rates (21% vs. 41%), less alcohol craving, and fewer drinking days compared with patients who received placebo, but these results depended on the specific analysis used. The clinical use of naltre ...
... alcohol-dependent patients, the group of patients receiving naltrexone were shown to have lower relapse rates (21% vs. 41%), less alcohol craving, and fewer drinking days compared with patients who received placebo, but these results depended on the specific analysis used. The clinical use of naltre ...
Regulation of tumor necrosis factor
... by the patient [4], a new set of classification criteria was developed in a collaborative effort by the American College of Rheumatology (ACR) and the European League Against Rheumatism. Prior to 2010, the criteria had not been updated since 1987. This former set of criteria had frequently been crit ...
... by the patient [4], a new set of classification criteria was developed in a collaborative effort by the American College of Rheumatology (ACR) and the European League Against Rheumatism. Prior to 2010, the criteria had not been updated since 1987. This former set of criteria had frequently been crit ...
Procedures for Administering Injectable Drugs
... You have to set your pump in ml/hour. There are 60 minutes in an hour so multiply 3.6266666ml/minute by 60 to get 217.6ml/hour. You may have to round this figure to 218ml/hour to set your pump. P.S. If the infusion time is in hours then you don’t need to multiply the answer by 60. Also notice that t ...
... You have to set your pump in ml/hour. There are 60 minutes in an hour so multiply 3.6266666ml/minute by 60 to get 217.6ml/hour. You may have to round this figure to 218ml/hour to set your pump. P.S. If the infusion time is in hours then you don’t need to multiply the answer by 60. Also notice that t ...
Product Information for fluticasone propionate and azelastine
... DYLASTINE 125/50 was not studied in any special populations, and no gender-specific pharmacokinetic data have been obtained. The following data are available for the individual active component, azelastine: ...
... DYLASTINE 125/50 was not studied in any special populations, and no gender-specific pharmacokinetic data have been obtained. The following data are available for the individual active component, azelastine: ...
antidotes in depth (a20) - Goldfrank`s Toxicologic Emergencies
... probably reflecting distribution into different compartments, as well as excretion and catabolism. Free serum digoxin concentrations were undetectable for the first 9 hours, then rose to a peak of 2 ng/mL at 16 hours, and fell to 1.5 ng/mL at both 36 hours and 56 hours at which time sampling stopped ...
... probably reflecting distribution into different compartments, as well as excretion and catabolism. Free serum digoxin concentrations were undetectable for the first 9 hours, then rose to a peak of 2 ng/mL at 16 hours, and fell to 1.5 ng/mL at both 36 hours and 56 hours at which time sampling stopped ...
Apnea in the Newborn
... Indications for using continuous positive airway pressure (CPAP) in the treatment of apnea include a failure to respond to methylxanthine therapy11. We avoid using doxapram and use CPAP as the next step after aminophylline in the algorithm for management of apnea. Indications for starting CPAP in a ...
... Indications for using continuous positive airway pressure (CPAP) in the treatment of apnea include a failure to respond to methylxanthine therapy11. We avoid using doxapram and use CPAP as the next step after aminophylline in the algorithm for management of apnea. Indications for starting CPAP in a ...
1. Exposure Data - IARC Monographs
... more neoplasms were found in the drug-treated patients because subsequent thyroidectomy was more frequent in this group (30% of drug-treated patients, as compared with 0.5% of those initially treated with 131I and 1.2% of those treated with primary thyroidectomy), which provided more opportunity for ...
... more neoplasms were found in the drug-treated patients because subsequent thyroidectomy was more frequent in this group (30% of drug-treated patients, as compared with 0.5% of those initially treated with 131I and 1.2% of those treated with primary thyroidectomy), which provided more opportunity for ...
EVALUATION OF ANTI-INFLAMMATORY ACTIVITY OF ALCOHOLIC EXTRACT OF LEAVES OF
... the mean values for control, Diclofenac, and the test compound Leucas aspera with 3 different doses to be, 0.62, 0.2436, 0.402, 0.336, 0.2442 respectively, while the percentage inhibition by carrageenan induced paw edema method from 0-4 hours for the standard ( Diclofenac ) was 60.70%, and for the 3 ...
... the mean values for control, Diclofenac, and the test compound Leucas aspera with 3 different doses to be, 0.62, 0.2436, 0.402, 0.336, 0.2442 respectively, while the percentage inhibition by carrageenan induced paw edema method from 0-4 hours for the standard ( Diclofenac ) was 60.70%, and for the 3 ...
Truvada - Gilead Sciences, Inc.
... consistent with acute viral infection are present and recent (<1 month) exposures are suspected, delay starting PrEP for at least one month and reconfirm negative HIV-1 status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. ...
... consistent with acute viral infection are present and recent (<1 month) exposures are suspected, delay starting PrEP for at least one month and reconfirm negative HIV-1 status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. ...
clinical pharmacology of rocuronium bromide
... Neuromuscular Agents: Costs of Care • Cost of care acquisition cost • The real, substantial savings accrue from use of intermediate- and short-acting drugs because: • Inexpensive, long-acting drugs are associated with prolonged postoperative recovery 1 • Fast recovery means shorter risk periods o ...
... Neuromuscular Agents: Costs of Care • Cost of care acquisition cost • The real, substantial savings accrue from use of intermediate- and short-acting drugs because: • Inexpensive, long-acting drugs are associated with prolonged postoperative recovery 1 • Fast recovery means shorter risk periods o ...
Product Monograph Template - Standard - GlaxoSmithKline
... Post-hoc analysis of the SMART trial data suggests that the risks may be lower in patients who were using inhaled corticosteroids (ICS) at study entry. However, these post-hoc analysis results are not conclusive (see CLINICAL TRIALS: Salmeterol Multi-center Asthma Research Trial (SMART)). Currently ...
... Post-hoc analysis of the SMART trial data suggests that the risks may be lower in patients who were using inhaled corticosteroids (ICS) at study entry. However, these post-hoc analysis results are not conclusive (see CLINICAL TRIALS: Salmeterol Multi-center Asthma Research Trial (SMART)). Currently ...
Ceftriaxone-AFT
... liver damage, there is no need for the dosage to be reduced provided renal function is intact. In cases of concomitant severe renal and hepatic dysfunction, the plasma concentrations of ceftriaxone should be determined at regular intervals and if necessary the dose adjusted. In patients undergoing ...
... liver damage, there is no need for the dosage to be reduced provided renal function is intact. In cases of concomitant severe renal and hepatic dysfunction, the plasma concentrations of ceftriaxone should be determined at regular intervals and if necessary the dose adjusted. In patients undergoing ...
ESC 2003
... • The very high level of inhibition needed is not tolerated long term One can titrate oral thrombin inhibitors to the right dose • Dose is well tolerated in the long-term Heartbeat – Sept 2003 ...
... • The very high level of inhibition needed is not tolerated long term One can titrate oral thrombin inhibitors to the right dose • Dose is well tolerated in the long-term Heartbeat – Sept 2003 ...
effect of piperine, a major component of black pepper, on the
... Each value is the mean ± S.E.M. of 6 observations. Statistically significant from the values obtained for domperidone alone (* P<0.05, ** P<0.01 and *** P<0.001). ...
... Each value is the mean ± S.E.M. of 6 observations. Statistically significant from the values obtained for domperidone alone (* P<0.05, ** P<0.01 and *** P<0.001). ...
VI. Overall conclusion and risk/benefit assessment
... This AusPAR describes the application by the sponsor to register a new strength of Xarelto (2.5 mg) for a new indication. The proposed additional indication for Xarelto (2.5 mg) is: Prevention of cardiovascular death, myocardial infarction and stent thrombosis in patients after an acute coronary syn ...
... This AusPAR describes the application by the sponsor to register a new strength of Xarelto (2.5 mg) for a new indication. The proposed additional indication for Xarelto (2.5 mg) is: Prevention of cardiovascular death, myocardial infarction and stent thrombosis in patients after an acute coronary syn ...